Cyclica

Toronto, Canada Founded: 2010 • Age: 16 yrs Acquired By Recursion
Online AI-interfacedpredictive analytics platform for drug discovery and testing
Request Access

About Cyclica

Cyclica is a company based in Toronto (Canada) founded in 2010 was acquired by Recursion in May 2023.. Cyclica has raised $21.06 million across 7 funding rounds from investors including Recursion Pharmaceuticals, Gates Foundation and Chiesi Pharmaceuticals. Cyclica operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Cyrus Biotechnology and Vividion Therapeutics, among others.

  • Headquarter Toronto, Canada
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Cyclica Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Technology → Artificial Intelligence & Machine Learning
Technology → Cloud, Data & Analytics Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $21.06 M (USD)

    in 7 rounds

  • Latest Funding Round
    $1.81 M (USD), Grant

    Nov 15, 2022

  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Recursion

    (May 08, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Cyclica
Headcount 50-200
Employee Profiles 4
Board Members and Advisors 4
Employee Profiles
People
Jonathan Mcclare
Senior Software Developer
People
Ganna Posternak
Drug Discovery Scientist
People
Jason Mitakidis
Founder
People
Shane Climie
VP of Corporate Development

Unlock access to complete

Board Members and Advisors
people
Mostafa Analoui
Co-Chairman

Unlock access to complete

Funding Insights of Cyclica

Cyclica has successfully raised a total of $21.06M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $1.81 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 7
  • Last Round Grant — $1.8M
  • First Round

    (10 Dec 2013)

  • Investors Count 9
Date Amount Transaction Name Valuation Lead Investors Investors
Nov, 2022 Amount Grant - Cyclica Valuation

investors

Apr, 2020 Amount Series B - Cyclica Valuation Drive Capital
Jul, 2017 Amount Series A - Cyclica Valuation GreenSky
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Cyclica

Cyclica has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Recursion Pharmaceuticals, Gates Foundation and Chiesi Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm focused on pre-seed and seed stage investments
Founded Year Domain Location
Early stage Canadian B2B startups are funded by GreenSky Ventures.
Founded Year Domain Location
-
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Cyclica

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Cyclica

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Cyclica Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Cyclica

Cyclica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Cyrus Biotechnology and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Cloud-based protein-modeling software is developed for drug discovery.
domain founded_year HQ Location
Developing novel drugs based on a proteome-wide ligand and target discovery platform
domain founded_year HQ Location
RNA-editing technologies are provided for precision medicine applications.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Cyclica

Frequently Asked Questions about Cyclica

When was Cyclica founded?

Cyclica was founded in 2010 and raised its 1st funding round 3 years after it was founded.

Where is Cyclica located?

Cyclica is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.

Is Cyclica a funded company?

Cyclica is a funded company, having raised a total of $21.06M across 7 funding rounds to date. The company's 1st funding round was a Series A of $2.25M, raised on Dec 10, 2013.

What does Cyclica do?

Online AI-interface predictive analytics platform for drug discovery and testing. It is a biotechnology company that offers a biomolecular analytics platform for proteome docking. It uses proprietary algorithms and databases to improve drug discovery pipelines by identifying risks such as adverse effects, contraindications, and lack of efficacy. It uses multi-channel systems for evaluating and comparing small molecules to predict the reaction with the human body and searches for all proteins that have potential drug-protein interactions. It also offers a proprietary database of bacterial and viral proteomes that can be used to identify new treatments for infectious diseases.

Who are the top competitors of Cyclica?

Cyclica's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.

Who are Cyclica's investors?

Cyclica has 10 investors. Key investors include Recursion Pharmaceuticals, Gates Foundation, Chiesi Pharmaceuticals, StartUp Health, and Drive Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available